paediatrics Brussels 17

1549 / 1708

P = .07
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
14 14 12 10 8 7 6 6 6 5 4
35 34 31 29 25 24 18 13 7 4 3
No. at risk
CERN Cohort
C
P = .1
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
15 14 12 10 10 9 8 6 5 4 3
22 21 18 17 14 12 9 6 4 3 3
No. at risk
D
P = .6
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
30 26 22 17 13 12 9 9 9 8 6
84 79 66 54 46 37 31 26 10 8 5
No. at risk
Burdenko Cohort
E
P = .6
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
27 25 20 16 10 6 3 1 1 0 0
70 63 53 38 31 23 17 10 7 7 5
No. at risk
F
P = .003
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
39 26 20 15 11 11 11 11 11 8 6 No first-line XRT
137 122 103 86 68 56 43 37 28 21 16 First-line XRT
No. at risk
GENE Cohort
GTR A B
P < .001
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
No first-line XRT
First-line XRT
21 7 4 3 3 3 2 2 2 2 2 No first-line XRT
66 51 46 35 31 19 15 11 9 7 5 First-line XRT
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
No first-line XRT
First-line XRT
No. at risk
STR
Fig A6. Overall survival (OS) of EPN_PFA for the four cohorts divided by (A, C, and E) gross total resection (GTR) and (B, D, and F) subtotal resection (STR). P values were
determined using the log-rank test. CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; XRT, radiotherapy.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ramaswamy et al
from 139.18.224.1
Information downloaded from and provided by at UNIVERSITAETSKLINIKUM LEIPZIG on June 20, 2016
Copyright © 2016 American S ciety of Clinical Oncology. All rights reserved.